Market Trends of Germany Respiratory Devices Industry
This section covers the major market trends shaping the Germany Respiratory Devices Market according to our research experts:
Ventilators in Germany Respiratory Device is Estimated to Witness Healthy Growth in Future.
Ventilators are estimated to witness healthy growth in the future, attributed to the growing prevalence of respiratory disorders and the growing geriatric population. Ventilation equipment has been in high demand as a result of the COVID-19 outbreak. A ventilator is a type of medical equipment that provides mechanical ventilation by moving breathable air into and out of the lungs to provide breaths to patients who are physically unable to breathe or insufficiently breathing.
An increase in product launches by the market players is expected to boost the segment's growth over the forecast period. In October 2021, the launch of Luisa was announced; it is the third-generation ventilator developed and manufactured by Lowenstein Medical in Germany and marketed in Europe since 2020. It can be prescribed to patients diagnosed with chronic respiratory failure due to chronic obstructive pulmonary disease (COPD) and interstitial lung disease (ILD).
Additionally, various initiatives taken by the market players are expected to boost the market growth in the country. For instance, in March 2022, German authorities prevented the Chinese Aeonmed Group from acquiring German medical equipment producer Heyer Medical AG. Such initiatives by the market players are expected to boost the segment's growth over the forecast period. In September 2021, Germany donated five ventilators worth UGX 407.5 million (EUR 98,150) to Mulago National Referral Hospital and Mbarara Regional Referral Hospital. Thus, all aforementioned factors are expected to boost the segment's growth over the forecast period.
Inhalers Segment is Expected to Witness Healthy Growth Over the Forecast Period
An inhaler is a device used to deliver medication to the lungs and airways. It is mainly used to treat or prevent respiratory diseases such as asthma, chronic obstructive pulmonary disease (COPD), or cystic fibrosis. Inhalers are medications inhaled through the mouth and into the lungs, which help relax the muscles that tighten around the airways. Inhalers help open up the airways, allowing more air to move in and out of the lungs and helping the patient breathe more easily.
The increasing cases of respiratory diseases, such as hay fever, chronic obstructive pulmonary disease (COPD), and asthma, are the major factor propelling the segment's growth. In Germany, the most prevalent respiratory allergy in the country is hay fever, which is caused due to the cedar pollen spread throughout the country. According to the study published in the Journal of Asthma Allergy in July 2022, asthma is one of Germany's most common chronic diseases, affecting 4-5% of all adults and 10% of children each year. Thus, the significant burden of respiratory diseases in the country drives the demand for respiratory devices such as inhalers, thereby boosting the growth of the segment.
The study published in the International Journal of Chronic Obstructive Pulmonary Disease in July 2022 reported that single-inhaler triple therapy (efSITT), which includes inhaled corticosteroid (ICS) beclomethasone, long-acting 2-agonist (LABA) formoterol, and long-acting muscarinic antagonist (LAMA) glycopyrronium, were effective against respiratory diseases and improved COPD-specific symptoms and lung function parameters in COPD patients. The advantages and effectiveness of inhalers for COPD diseases are expected to propel the growth of the segment.
